

**Grant Thornton** Statsautoriseret Revisionspartnerselskab

Stockholmsgade 45 2100 København Ø CVR-nr. 34209936

T (+45) 33 110 220

www.grantthornton.dk

# **TannerMedico A/S**

Agern Allé 1, 2970 Hørsholm

Company reg. no. 28 69 57 80

**Annual report** 

# 1 January - 31 December 2021

The annual report was submitted and approved by the general meeting on the 25 May 2022.

Peter Jørgen Giersing Chairman of the meeting

Notes:

<sup>•</sup> To ensure the greatest possible applicability of this document, IAS/IFRS English terminology has been used.

<sup>•</sup> Please note that decimal points have not been used in the usual English way. This means that for instance DKK 146.940 means the amount of DKK 146,940, and that 23,5 % means 23.5 %.

# Contents

	Page
Reports	
Management's statement	1
Independent auditor's report	2
Management's review	
Company information	5
Management's review	6
Financial statements 1 January - 31 December 2021	
Accounting policies	7
Income statement	11
Balance sheet	12
Notes	14

# **Management's statement**

Today, the Board of Directors and the Managing Director have approved the annual report of TannerMedico A/S for the financial year 1 January - 31 December 2021.

The annual report has been prepared in accordance with the Danish Financial Statements Act.

We consider the chosen accounting policy to be appropriate, and in our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2021 and of the results of the Company's operations for the financial year 1 January -31 December 2021.

Further, in our opinion, the Management's review gives a true and fair review of the matters discussed in the Management's review.

We recommend that the annual report be approved at the Annual General Meeting.

Hørsholm, 25 May 2022

**Managing Director** 

René Arnfeldt Møller

**Board of directors** 

Peter Jørgen Giersing

René Arnfeldt Møller

Stephanie Cecilla Arnfeldt Castella

Jacob Ziirsten Hatt

#### **Independent auditor's report**

#### To the Shareholder of TannerMedico A/S

#### Opinion

We have audited the financial statements of TannerMedico A/S for the financial year 1 January - 31 December 2021, which comprise a summary of significant accounting policies, income statement, balance sheet and notes, for the Company. The financial statements are prepared under the Danish Financial Statements Act.

In our opinion, the financial statements give a true and fair view of the financial position of the Company at 31 December 2021, and of the results of the Company's operations for the financial year 1 January - 31 December 2021 in accordance with the Danish Financial Statements Act.

#### **Basis for Opinion**

We conducted our audit in accordance with International Standards on Auditing (ISAs) and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the "Auditor's Responsibilities for the Audit of the Financial Statements" section of our report. We are independent of the Company in accordance with the International Ethics Standards Board for Accountants' International Code of Ethics for Professional Accountants (IESBA Code) and the additional ethical requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the IESBA Code. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

#### Management's Responsibilities for the Financial Statements

Management is responsible for the preparation of financial statements that give a true and fair view in accordance with the Danish Financial Statements Act, and for such internal control as Management determines is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, Management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting in preparing the financial statements unless Management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

#### Auditor's Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

#### **Independent auditor's report**

As part of an audit conducted in accordance with ISAs and the additional requirements applicable in Denmark, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by Management.
- Conclude on the appropriateness of Management's use of the going concern basis of accounting in preparing the financial statements and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the financial statements, including the disclosures, and whether the financial statements represent the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

#### Statement on Management's Review

Management is responsible for Management's Review.

Our opinion on the financial statements does not cover Management's Review, and we do not express any form of assurance conclusion thereon.

#### **Independent auditor's report**

In connection with our audit of the financial statements, our responsibility is to read Management's Review and, in doing so, consider whether Management's Review is materially inconsistent with the financial statements or our knowledge obtained during the audit, or otherwise appears to be materially misstated.

Moreover, it is our responsibility to consider whether Management's Review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we conclude that Management's Review is in accordance with the financial statements and has been prepared in accordance with the requirements of the Danish Financial Statement Act. We did not identify any material misstatement of Management's Review.

Copenhagen, 25 May 2022

**Grant Thornton** State Authorised Public Accountants Company reg. no. 34 20 99 36

Michael Winther Rasmussen State Authorised Public Accountant mne28708 Jacob Helly Juell-Hansen State Authorised Public Accountant mne36169

# **Company information**

The company	TannerMedico A/S Agern Allé 1 2970 Hørsholm	
	Company reg. no.	
	Financial year:	1 January - 31 December
Board of directors	Peter Jørgen Giersing René Arnfeldt Møller Stephanie Cecilla Arnfeldt Castella Jacob Ziirsten Hatt	
Managing Director	René Arnfeldt Mølle	r
Auditors	Grant Thornton, Statsautoriseret Revisionspartnerselskab Stockholmsgade 45 2100 København Ø	
Parent company	Ramas International	ApS

# Management's review

#### The principal activities of the company

TannerMedico A/S manufactures and internationally distributes products within the sleep category, including Asonor Anti Snoring Solution.

The production of Asonor Anti Snoring Solution is in accordance with International Medicines Regulations (CGMP) and the company's strategy is to market Asonor internationally via online platforms and through a network of distributors who have an in-depth knowledge of their local market conditions.

Asonor Anti Snoring Solution is registered as Medical Equipment by the medical authorities of more than 70 countries.

During the financial year, the company completed the development of a new product under the name Asonor Sleep Support, which naturally contributes to better sleep. Asonor Sleep Support was launched in the beginning of 2022 and it is the company's plan to sell the new product as a natural supplement and through the same channels as Asonor Anti Snoring Solution.

#### Development in activities and financial matters

The gross profit for the year amounts to TDKK 2.461 against TDKK 2.163 last year. The ordinary result after tax amounts to TDKK 389 against TDKK 102 last year.

The income statement for 2021 is affected in a negative way by expensed development costs in the level of approx. 900 TDKK.

The result for the year is to a limited extent affected by longer delivery times at subcontractors, but in addition as expected.

## Events occurring after the end of the financial year

The company's continued operation is not considered to be threatened by the spillover effects of the "Corona crisis" and the war in Ukraine, as demand for the company's products is assessed to be intact or increasing on both online platforms and in physical stores such as pharmacies, as well as in new markets.

The annual report for TannerMedico A/S has been presented in accordance with the Danish Financial Statements Act regulations concerning reporting class B enterprises. Furthermore, the company has decided to comply with certain rules applying to reporting class C enterprises.

The accounting policies are unchanged from last year, and the annual report is presented in DKK.

#### **Recognition and measurement in general**

Income is recognised in the income statement concurrently with its realisation, including the recognition of value adjustments of financial assets and liabilities. Likewise, all costs are recognised in the income statement, including depreciations amortisations, writedowns for impairment, provisions, and reversals due to changes in estimated amounts previously recognised in the income statement.

Assets are recognised in the statement of financial position when it seems probable that future economic benefits will flow to the company and the value of the asset can be reliably measured.

Liabilities are recognised in the statement of financial position when it is seems probable that future economic benefits will flow out of the company and the value of the liability can be reliably measured.

Assets and liabilities are measured at cost at the initial recognition. Hereafter, assets and liabilities are measured as described below for each individual accounting item.

#### Income statement

#### **Gross profit**

Gross profit comprises the revenue, changes in inventories of finished goods, other operating income, and external cost

Revenue is recognised in the income statement if delivery and passing of risk to the buyer have taken place before the end of the year and if the income can be determined reliably and inflow is anticipated. Recognition of revenue is exclusive of VAT and taxes and less any discounts relating directly to sales.

Cost of sales comprises costs concerning purchase of raw materials and consumables less discounts and changes in inventories.

Other operating income comprises items of a secondary nature as regards the principal activities of the enterprise.

#### **Government grants**

Other external expenses comprise expenses incurred for distribution, sales, advertising, administration, premises, loss on receivables, and operational leasing costs.

#### Staff costs

Staff costs include salaries and wages, including holiday allowances, pensions, and other social security costs, etc., for staff members. Staff costs are less government reimbursements.

#### Depreciation, amortisation, and writedown for impairment

Depreciation, amortisation, and writedown for impairment comprise depreciation, amortisation, and writedown for the year and profit and loss on the disposal of intangible and tangible assets.

#### Financial income and expenses

Financial income and expenses are recognised in the income statement with the amounts concerning the financial year. Financial income and expenses comprise interest income and expenses, financial expenses from financial leasing, realised and unrealised capital gains and losses relating to securities, debt and transactions in foreign currency, amortisation of financial assets and liabilities as well as surcharges and reimbursements under the advance tax scheme, etc.

#### Tax on net profit or loss for the year

Tax for the year comprises the current income tax for the year and changes in deferred tax and is recognised in the income statement with the share attributable to the net profit or loss for the year and directly in equity with the share attributable to entries directly in equity.

The company is subject to Danish rules on compulsory joint taxation of Danish group enterprises.

The current Danish income tax is allocated among the jointly taxed companies proportional to their respective taxable income (full allocation with reimbursement of tax losses).

## Statement of financial position

#### Intangible assets

#### Development projects, patents, and licences

Development costs and internally generated rights are measured at cost less accrued amortisation. Development costs are amortised on a straightline basis over a period of 10 years.

Patents and licenses are measured at cost less accrued amortisation. Patents are amortised on a straightline basis over the remaining patent period and licenses are amortised over the contract period, however, for a maximum of 10 years.

Profit and loss from the sale of development projects, patents, and licenses are measured as the difference between the sales price less sales costs and the carrying amount at the time of sale. Profit or loss is recognised in the income statement under amortisation and writedown for impairment.

#### Investments

#### Deposits

Deposits are measured at amortised cost and represent lease deposits, etc.

#### Inventories

Inventories are measured at cost according to the FIFO method. In cases when the net realisable value of the inventories is lower than the cost, the latter is written down for impairment to this lower value.

Costs of goods for resale, raw materials, and consumables comprise acquisition costs plus delivery costs.

#### Receivables

Receivables are measured at amortised cost, which usually corresponds to nominal value.

#### Prepayments

Prepaymentsrecognised under assets comprise incurred costs concerning the following financial year.

#### Financial instruments and equity investments

Financial instruments and equity investments recognised under current assets consist of listed shares and bonds which are measured at fair value on the reporting date. Unlisted equity investments are measured at cost. Writedown takes place to the recoverable amount if this value is lower than the carrying amount.

#### Cash and cash equivalents

Cash and cash equivalents comprise cash at bank and on hand.

#### Equity

#### Share premium

Share premium comprises premium payments made in connection with the issue of shares. Costs incurred for carrying through an issue are deducted from the premium.

The premium reserve can be used for dividend, for issuing bonus shares, and for covering losses.

#### **Reserve for development costs**

The reserve for development costs comprises recognised development costs less related deferred tax liabilities.

The reserve cannot be used as dividends or for covering losses.

The reserve is reduced or dissolved if the recognised development costs are amortised or abandoned. This is done by direct transfer to the distributable reserves of the equity.

#### Income tax and deferred tax

Current tax liabilities and current tax receivable are recognised in the statement of financial position as calculated tax on the taxable income for the year, adjusted for tax of previous years' taxable income and for tax paid on account.

The company is jointly taxed with consolidated Danish companies. The current corporate income tax is distributed between the jointly taxed companies in proportion to their taxable income and with full distribution with reimbursement as to tax losses. The jointly taxed companies are comprised by the Danish tax prepayment scheme.

Joint taxation contributions payable and receivable are recognised in the statement of financial position as "Income tax receivable" or "Income tax payable".

According to the rules of joint taxation, TannerMedico A/S is unlimitedly, jointly, and severally liable to pay the Danish tax authorities the total income tax, including withholding tax on interest, royalties, and dividends, arising from the jointly taxed group of companies.

Deferred tax is measured on the basis of temporary differences in assets and liabilities with a focus on the statement of financial position. Deferred tax is measured at net realisable value.

Adjustments take place in relation to deferred tax concerning elimination of unrealised intercompany gains and losses.

Deferred tax is measured based on the tax rules and tax rates applying under the legislation prevailing in the respective countries on the reporting date when the deferred tax is expected to be released as current tax. Changes in deferred tax due to changed tax rates are recognised in the income statement, except for items included directly in the equity.

Deferred tax assets, including the tax value of tax losses allowed for carryforward, are recognised at the value at which they are expected to be realisable, either by settlement against tax of future earnings or by set-off in deferred tax liabilities within the same legal tax unit. Any deferred net tax assets are measured at net realisable value.

#### Liabilities other than provisions

Other liabilities concerning payables to suppliers, group enterprises, and other payables are measured at amortised cost which usually corresponds to the nominal value.

# Income statement 1 January - 31 December

Amounts concerning 2021: DKK. Amounts concerning 2020: DKK thousand.

Not	<u>e</u>	2021	2020
	Gross profit	2.460.902	2.163
2	Staff costs	-2.336.960	-2.040
	Depreciation and impairment of non-current assets	-149.334	-133
	Operating profit	-25.392	-10
	Other financial income	618.667	246
	Other financial expenses	-93.939	-202
	Pre-tax net profit or loss	499.336	34
	Tax on net profit or loss for the year	-110.105	68
	Net profit or loss for the year	389.231	102
	Proposed appropriation of net profit:		
	Transferred to retained earnings	389.231	102
	Total allocations and transfers	389.231	102

# **Balance sheet at 31 December**

Amounts concerning 2021: DKK. Amounts concerning 2020: DKK thousand.

	Assets		
Not	e	2021	2020
	Non-current assets		
3	Patents, licenses, trademarks, and similar rights	788.769	938
	Total intangible assets	788.769	938
4	Deposits	35.008	32
	Total investments	35.008	32
	Total non-current assets	823.777	970
	Current assets		
	Manufactured goods and goods for resale	1.547.893	915
	Total inventories	1.547.893	915
	Trade receivables	2.764.705	3.133
	Deferred tax assets	0	68
	Other receivables	18.527	202
	Prepayments	56.206	47
	Total receivables	2.839.438	3.450
	Other financial investments	1.437.744	839
	Total investments	1.437.744	839
	Cash and cash equivalents	214.959	789
	Total current assets	6.040.034	5.993
	Total assets	6.863.811	6.963

# **Balance sheet at 31 December**

Amounts concerning 2021: DKK. Amounts concerning 2020: DKK thousand.

Equity a	nd lia	bilities
----------	--------	----------

Not	<u>e</u>	2021	2020
	Equity		
5	Contributed capital	750.000	750
6	Share premium	0	510
7	Retained earnings	4.867.609	3.969
	Total equity	5.617.609	5.229
	Provisions		
	Provisions for deferred tax	53.712	0
	Total provisions	53.712	0
	Liabilities other than provisions		
	Bank loans	415.072	0
	Trade payables	600.666	866
	Payables to subsidiaries	1.153	595
	Payables to shareholders and management	2.023	11
	Other payables	173.576	262
	Total short term liabilities other than provisions	1.192.490	1.734
	Total liabilities other than provisions	1.192.490	1.734
	Total equity and liabilities	6.863.811	6.963

1 Special items

8 Charges and security

9 Contingencies

#### Notes

2.

Amounts concerning 2021: DKK. Amounts concerning 2020: DKK thousand.

2021 2020

#### 1. Special items

Special items include significant income and expenses of a special nature relative to the enterprise's ordinary operating activities, such as the cost of extensive structuring of processes and fundamental structural adjustments and any related gains on disposal and losses which, over time, have a significant impact. Special items also include other significant amounts of a nonrecurring nature.

Special items for the year are specified below, indicating where they are recognised in the income statement.

Income:		
Public payroll compensation	60.743	143.655
	60.743	143.655
Special items are recognised in the following items in the financial statements:		
Gross Profit	60.743	143.655
Profit of special items, net	60.743	143.655
Staff costs		
Salaries and wages	2.081.728	1.886
Pension costs	235.729	1.000
Other costs for social security	19.503	15
	2.336.960	2.040
Average number of employees	3	3

# Notes

Amounts concerning 2021: DKK. Amounts concerning 2020: DKK thousand.

		31/12 2021	31/12 2020
3.	Patents, licenses, trademarks, and similar rights		
5.	Cost 1 January 2021	1.493.336	1.310
	Additions during the year	1.495.550	1.310
	Cost 31 December 2021	1.493.336	1.493
	Amortisation and writedown 1 January 2021	-555.233	-422
	Amortisation for the year	-149.334	-133
	Amortisation and writedown 31 December 2021	-704.567	-555
	Carrying amount, 31 December 2021	788.769	938
4.	Deposits		
	Cost 1 January 2021	31.637	32
	Additions during the year	3.371	0
	Cost 31 December 2021	35.008	32
	Carrying amount, 31 December 2021	35.008	32
5.	Contributed capital		
	Contributed capital 1 January 2021	750.000	750
		750.000	750
6.	Share premium		
	Share premium 1 January 2021	510.000	510
	Transferred to retained earnings	-510.000	0
		0	510

#### Notes

Amounts concerning 2021: DKK. Amounts concerning 2020: DKK thousand.

		31/12 2021	31/12 2020
7.	Retained earnings		
	Retained earnings 1 January 2021	3.968.378	3.867
	Profit or loss for the year brought forward	389.231	102
	Transferred from share premium	510.000	0
		4.867.609	3.969

#### 8. Charges and security

For bank loans, DKK 415.073, the company has provided security in company assets representing a nominal value of DKK 1.000.000. This security comprises the assets below, stating the carrying amounts:

	DKK in
	thousands
Trade receivables	2.765

# 9. Contingencies Contingent liabilities

	DKK in
	thousands
Lease liabilities	35
Total contingent liabilities	35

#### Joint taxation

With Ramas International A/S, company reg. no 89504619 as administration company, the company is subject to the Danish scheme of joint taxation and unlimitedly, jointly, and severally liable, along with the other jointly taxed companies, for the total corporation tax.

The company is unlimitedly, jointly, and severally liable, along with the other jointly taxed companies, for any obligations to withhold tax on interest, royalties, and dividends.

Any subsequent adjustments of corporate taxes or withholding tax, etc., may result in changes in the company's liabilities.